Literature DB >> 10779166

Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev.

M R Mautino1, W J Ramsey, J Reiser, R A Morgan.   

Abstract

As a first step toward the development of HIV-based conditionally replicating defective interfering particles expressing trans-dominant Rev (TdRev), we studied whether mutation of the splicing signals and replacement of the RRE by the SRV-1 CTE would render these vectors less sensitive to TdRev. Vectors with mutations in the splicing signals (SD-/RRE+) yielded high titers (5 X 10(6) CFU/ml) and showed higher levels of cytoplasmic unspliced mRNA than the corresponding SD+/RRE+ vectors either in the absence of Rev, in the presence of TdRev, or in the presence of both TdRev and Rev. Proviral copies of SD-/RRE+ vectors were rescued more efficiently than SD+/RRE+ vectors when TdRev was expressed. Vectors with the SRV-1 CTE (SD+/CTE+ and SD-/CTE+) expressed high levels of cytoplasmic unspliced mRNA in the absence of Rev expression. Titers obtained with the SD-/CTE+ vectors (10(6) CFU/ml) were higher than the titers obtained with SD+/CTE+ vectors. We also tested the effect of other structural modifications such as the orientation of the expression cassette and the presence of the central polypurine tract (cPPT/CTS). We show that an expression cassette cloned in the reverse orientation with respect to the LTRs or elimination of the cPPT/CTS element severely affected vector titers. We also demonstrated that these vectors can be efficiently mobilized from their proviral state by HIV trans-complementing functions, and transduced into secondary target cells without suffering any genomic rearrangement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779166     DOI: 10.1089/10430340050015509

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

3.  Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid.

Authors:  J Vellinga; J de Vrij; S Myhre; T Uil; P Martineau; L Lindholm; R C Hoeben
Journal:  Gene Ther       Date:  2007-02-01       Impact factor: 5.250

4.  Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway.

Authors:  Narasimhachar Srinivasakumar
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

5.  HIV-based lentiviral vectors: origin and sequence differences.

Authors:  Nathan M Johnson; Anna Francesca Alvarado; Trey N Moffatt; Joshua M Edavettal; Tarun A Swaminathan; Stephen E Braun
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-27       Impact factor: 6.698

6.  The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA.

Authors:  Bastian Grewe; Katrin Ehrhardt; Bianca Hoffmann; Maik Blissenbach; Sabine Brandt; Klaus Uberla
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

7.  Lentiviral vector design using alternative RNA export elements.

Authors:  Taekeun Oh; Ali Bajwa; Guangfu Jia; Frank Park
Journal:  Retrovirology       Date:  2007-06-05       Impact factor: 4.602

8.  Substitution of the Rev-response element in an HIV-1-based gene delivery system with that of SIVmac239 allows efficient delivery of Rev M10 into T-lymphocytes.

Authors:  Narasimhachar Srinivasakumar
Journal:  AIDS Res Ther       Date:  2008-06-05       Impact factor: 2.250

Review 9.  Exploiting Genetic Interference for Antiviral Therapy.

Authors:  Elizabeth J Tanner; Karla A Kirkegaard; Leor S Weinberger
Journal:  PLoS Genet       Date:  2016-05-05       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.